ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T. Williamson(Institute of Cancer Research), Christopher J. Lord(Institute of Cancer Research), Peter B. Vermulen(Institute of Cancer Research), Colm J. Ryan(University College Dublin), James Campbell(Proteome Sciences (United Kingdom)), Helen N. Pemberton(Institute of Cancer Research), Rumana Rafiq(Institute of Cancer Research), Aditi Gulati(Institute of Cancer Research), Jeffrey C. Francis(Institute of Cancer Research), Nicholas Badham(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Rowan Miller(Queen Mary University of London), Philip M. Reaper(Vertex Pharmaceuticals (United Kingdom)), Samuel E. Jones(Institute of Cancer Research), John R. Pollard(Vertex Pharmaceuticals (United Kingdom)), Asha Konde(Institute of Cancer Research), Andrew R. Reynolds(Breast Cancer Now), Rachel Brough(Institute of Cancer Research)
Cited by 386
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
|Angiogenesis|2014|732
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
|Cancer Discovery|2017|422